FDA is warning that when the multiple sclerosis (MS) medicine Gilenya (fingolimod) is stopped, the disease can become much worse than before the medicine was started or while it was being taken. This MS worsening is rare but can result in permanent disability.
Gilenya (fingolimod): Drug Safety Communication – Severe Worsening of Multiple Sclerosis After Stopping the Medicine
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA Takes Steps to Increase Availability of COVID-19 Vaccine
- Coronavirus (COVID-19) Update: June 11, 2021
- Viona Pharmaceuticals Inc., Issues Voluntary Nationwide Recall of Metformin HCl Extended-Release Tablets, USP 750 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
- Innova Medical Group Recalls Unauthorized SARS-CoV-2 Antigen Rapid Qualitative Test with Risk of False Test Results